Breaking Finance News

Trinity Biotech plc (ADR) (NASDAQ:TRIB) has been downgraded to Equal Weight in a statement by Stephens earlier today.

Stephens has downgraded Trinity Biotech plc (ADR) (NASDAQ:TRIB) to Equal Weight in a statement released on 10/05/2016.

Boasting a price of $6.46, Trinity Biotech plc (ADR) (NASDAQ:TRIB) traded 0.31% higher on the day. With the last stock price close down -43.76% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Trinity Biotech plc (ADR) has recorded a 50-day average of $12.21 and a two hundred day average of $11.68. Volume of trade was up over the average, with 398,351 shares of TRIB changing hands over the typical 216,062

Performance Chart

Trinity Biotech plc (ADR) (NASDAQ:TRIB)

With a total market value of $0, Trinity Biotech plc (ADR) has price-earnings ratio of 27.96 with a one year low of $5.76 and a one year high of $13.68 .

Brief Synopsis About Trinity Biotech plc (ADR) (NASDAQ:TRIB)

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech's blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.